A new clinical study has shown the effect of a S-AdenosylMethionine-based dietary supplement (SAMe 200 mg/die - Adonat SAMe ingredient manufactured by the biotech company Gnosis SpA - plus vitamin B-complex) in improving mild and moderate depressive symptoms. The nutraceutical product tested is commercialised by Abela Pharm (Belgrade, Serbia) under the brand name of Tensilen.
The study included 60 patients randomly allocated into two groups; the study group was treated with SAMe-vitamin B complex while the control group was administered a placebo once a day for three months.
To assess the efficacy in relieving depression symptoms, well-established research ratings were evaluated, such as the Hamilton Depression rating scale (HAMD17) and the Clinical Global Impression-Severity scale (CGI-S), as well as the Clinical Global Impression-Improvement scale (CGI-I) scores for the assessment of improvement or worsening after treatment relative to the baseline state.
The results of the study were positive for all the different kinds of tests, with significant differences between the study group and the control group.
The Hamilton Depression rating scale (HAMD17) scores on screening visit (T0) and after three months (T90) for the Study and Control groups This clinical study confirms the renewed interest of SAMe in the treatment of mood and as adjuvant in depressive symptoms.
A recent review of Sharma et al 2017 has taken into consideration 132 studies - 115 clinical and 17 preclinical – and has provided evidence that oral doses of SAMe are superior to placebo in ameliorating quality of life in depressed people.
To receive more information contact marketing@gnosis-bio.com and visit the website www.gnosis-bio.com/adonat-family